



EFLM
EUROPEAN FEDERATION OF CLINICAL CHEMISTRY
AND LABORATORY MEDICINE

ifcc
International Federation
of Clinical Chemistry
and Laboratory Medicine

Italian

- [Home](#)
- [Ultimo fascicolo](#)
 - [Casi clinici](#)
 - [Ahead of print](#)
 - [Archivio volumi](#)
- [Sottometti un articolo](#)
 - [Norme Autori](#)
 - [Cerca](#)

Volume:

Biochimica Clinica 2023; 47(3) 277-84

Pubblicato on-line:

Maggio 29, 2023

DOI:

10.19186/BC_2023.040

Scarica in PDF:

Autenticazione richiesta

Crioproteinemia: nuove frontiere per i clinici e il laboratorio

Cryoproteinemia: new frontiers for clinicians and the laboratory

AUTORI

Patrizia Natali^{1,12}, Daria Debbia^{1,12}, Teresa Troiano², Cecilia Napodano¹, Amelia Spinella^{3,12}, Gabriele Amati^{3,12}, Davide Filippini⁴, Roberta Zani⁵, Gaetano Alfano^{6,12}, Elisabetta Colaci⁷, Monica Maccaferri⁷, Giuliana Galassi^{8,12}, Marco Mazzoli^{8,12}, Alessandra Ariatti⁸, Umberto Basile⁹, Maria Teresa Mascia^{3,12}, Giovanni Palladini^{10,11}, Dilia Giuggioli^{3,12}, Gilda Sandri^{3,12} per conto di ALCRIaMO Modena¹²

¹Dipartimento Interaziendale Integrato di Medicina di Laboratorio e Anatomia Patologica, Azienda Unità Sanitaria Locale e Azienda Ospedaliero – Universitaria Policlinico di Modena

²Unità Operativa Complessa di Patologia Clinica Ospedaliera, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

³Struttura Complessa di Reumatologia, Dipartimento di Scienze Mediche e Chirurgiche Materno Infantili e dell'Adulto, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia

⁴Struttura Complessa di Reumatologia, Grande Ospedale Metropolitano ASST Niguarda, Milano

⁵Divisione Nefrologia, ASST Spedali Civili di Brescia

⁶Struttura Complessa di Nefrologia, Dialisi e Trapianto, Azienda Ospedaliero-Universitaria Policlinico di Modena

⁷Cattedra di Ematologia, Unità Operativa Complessa Ematologia, Dipartimento di Scienze Mediche e Chirurgiche Materno Infantili e dell'Adulto, Azienda Ospedaliera-Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia

⁸Struttura Complessa di Neurologia, Dipartimento di scienze biomediche, metaboliche e neuroscienze, Università di Modena e Reggio Emilia

⁹Unità Operativa Complessa Patologia Clinica, Azienda Unità Sanitaria Locale - Latina

¹⁰Dipartimento di Medicina Molecolare, Università degli Studi di Pavia

¹¹Medicina Generale 2 – Centro Amiloidosi Sistemiche e Malattie ad Alta Complessità, Fondazione IRCCS Policlinico San Matteo e Dipartimento di Medicina Molecolare, Università di Pavia

¹²Associazione Italiana Lotta alle Crioglobulinemie, Modena

ABSTRACT

Cryoproteinemia: new frontiers for clinicians and the laboratory

Cryoproteinemia is characterised by the presence of detectable proteins in both serum and plasma that precipitate at 4°C and dissolve at 37°C. Cryoglobulins are constituted by immunoglobulins and are detectable in both serum and plasma, whereas cryofibrinogen is detectable only in plasma. The importance of studying cryoproteinemia was the main theme of the meeting held in Modena in March 2023, entitled: Cryoglobulinemia. Laboratory and clinic, a fruitful collaboration for the correct management of a rare pathology – 4th edition, organised by the Italian Society of Clinical Biochemistry and Molecular Biology (SIBioC) and the Italian Association for the fight against Cryoglobulinaemia (ALCRI). The aim of this conference is to promote a dialogue between clinicians and laboratory professionals, highlighting the information that the clinician expects from the laboratory and the critical points that the laboratory faces when performing a test that is still predominantly performed manually. During the meeting, data from three laboratories were presented and compared, and a group of clinicians who deal with cryoproteinemia in different medical fields – rheumatologists, nephrologists, haematologists, and neurologists – contributed their experience in treating patients with cryoproteinemia. The collaboration between laboratory and clinic and the respective scientific societies (SIBioC and ALCRI) have made possible to draw a common line to guide both entities in their daily activity. The road seems long and complex, but a common system is emerging from this interaction, the fruits from which patient will benefit.

BIBLIOGRAFIA

BIBLIOGRAFIA

1. Natali P, Debbia D, Cucinelli MR, Trenti T, Amati G, Spinella A et al. Analysis of cryoproteins with a focus on cryofibrinogen: a study on 103 patients. *Chin Chem Lab Med* 2022;60:1796-803.
2. Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: an update in 2019. *Joint Bone Spine* 2019;86:707-13.
3. Blain H, Cacoub P, Musset L, Costedoat-Chalumeau N, Silberstein C, Chosidow O et al. Cryofibrinogenaemia: a study of 49 patients. *Clin Exp Immunol* 2000;120:253-60.
4. Mariscal-Rodríguez A, Villar Guimerans LM, López-Trascasa M, González MH, Naranjo EM. Laboratory guidelines for the diagnosis of patients with cryoglobulinaemic syndrome. *Rev Clin Esp* 2019;219:505-13.
5. Michaud M, Pourrat J. Cryofibrinogenemia. *J Clin Rheumatol* 2013;19:142-8.
6. Natali P, Debbia D, Turra F, Savoia M, Farci Santarcangeli D, Cigliana G et al. Indagine sulle modalità operative dell'analisi delle crioproteine: dalla fase preanalitica alla refertazione. *Biochim Clin* 2023;47:158-70.
7. Basile U, Gulli F, Gragnani L, Fognani E, Napodano C, Pocino K et al. IgG3 subclass: a possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection. *Dig Liver Dis* 2017;49:1233-9.
8. Napodano C, Gulli F, Rapaccini GL, Marino M, Basile U. Cryoglobulins: identification, classification, and novel biomarkers of mysterious proteins. *Adv Clin Chem* 2021;104:299-340.
9. Korst DR, Kratochvil CH. "Cryofibrinogen" in a case of lung neoplasm associated with thrombophlebitis migrans. *Blood* 1955;10:945-53.
10. Moiseev S, Luqmani R, Novikov P, Shevtsova T. Cryofibrinogenaemia. A neglected disease. *Rheumatology (Oxford)* 2017;56:1445-51.
11. Gómez-Fernández C, López-Sundh AE, González-Vela C, Ocejo-Vinyals JG, Mayor-Ibarguren A, Salas-Venero CA et al. High prevalence of cryofibrinogenemia in patients with chilblains during the COVID-19 outbreak. *Int J Dermatol* 2020;59:1475-84.
12. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. *Arthritis Rheum* 2012;64:843-53.
13. Delluc A, Saadoun D, Ghillani-Dalbin P, Sene D, Piette JC, Cacoub P. Cryofibrinogen in patients with hepatitis C virus infection. *Am J Med* 2008;121:624-31.
14. Soyfoo MS, Gou bella A, Cogan E, Wautrecht JC, Ocmant A, Stordeur P. Clinical significance of cryofibrinogenemia: Possible pathophysiological link with Raynaud's phenomenon. *J Rheumatol* 2012;39:119-24.
15. Belizna C, Loufrani L, Subra JF, Godin M, Jolly P, Vitecocq O et al. A 5-year prospective follow-up study in essential cryofibrinogenemia patients. *Autoimmun Rev* 2011;10:559-62.
16. Saadoun D, Elalamy I, Ghillani-Dalbin P, Sene D, Delluc A, Cacoub P et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. *Am J Med* 2009;122:1128-35.
17. Belizna CC, Tron F, Joly P, Godin M, Hamidou M, Lévesque H. Outcome of essential cryofibrinogenaemia in a series of 61 patients. *Rheumatology (Oxford)* 2008;47:205-7.
18. Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. *J Invest Dermatol* 2017;137:e11-6.
19. Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. *Allergy Immunol* 2011;40:78-83.

20. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2017;76:1327-39.
21. Barrett M, Prendiville J, Pardy B, Cream JJ. Cryofibrinogenaemia and acute gangrene in systemic sclerosis. *Postgrad Med J* 1986;62:935-6.
22. Van Den Hoogen F, Khanna D, Fransen J, Baron M, Tyndall A, Matucci-Cerinic M et al. 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative. *Arthritis Rheum* 2013;65:2737-47.
23. Humbert M, Kovacs G, Hoeper M, Berger RMF, Brida M, Carlsen J et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2022;38:3618-731.
24. Sudo M, Sakamaki Y, Hosojima M, Yamamoto S, Ito Y, Imai N et al. Cryofibrinogen-associated glomerulonephritis diagnosed by mass spectrometry and immunoelectron microscopy. *Hum Pathol Case Rep* 2019;15:83-7.
25. Sethi S, Yachoui R, Murray DL, Radhakrishnan J, Alexander MP. Cryofibrinogen-associated glomerulonephritis. *Am J Kidney Dis* 2017;69:302-8.
26. Terrier B, Izzedine H, Musset L, Ghillani P, Deray G, Saadoun D et al. Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders. *Nephrol Dial Transplant* 2011;26:3577-81.
27. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biological and clinical significance of cryoglobulins. *Am J Med* 1974;57:775-88.
28. Kolopp-Sarda M, Miossec P. Practical details for detection and interpretation of cryoglobulins. *Clin Chem* 2022;68:282-90.
29. Podell D, Packman C, Maniloff J, Abraham G. Characterization of monoclonal IgG cryoglobulins: fine-structural and morphological analysis. *Blood* 1987;69:677-81.
30. Néel A, Perrin F, Decaux O, Dejouie T, Tessoulin B, Halliez M et al. Long-term outcome of monoclonal (type 1) cryoglobulinemia. *Am J Hematol* 2014;89:156-61.
31. Kolopp-Sarda MN, Nombel A, Miossec P. Cryoglobulins today: detection and immunologic characteristics of 1,675 positive samples from 13,439 patients obtained over six years. *Arthritis Rheumatol* 2019;71:1904-12.
32. Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. *Blood* 2017;129:289-98.
33. Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: Analysis of clinical and biological characteristics of seven cases and review of the literature. *Leuk Lymphoma* 2013;54:767-77.
34. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinemia: a task force from the 8th International Workshop on Waldenström Macroglobulinemia. *Br J Haematol* 2016;175:77-86.
35. Biasiotta A, Casato M, La Cesa S, Colantuono S, Di Stefano G, Leone C et al. Clinical, neurophysiological, and skin biopsy findings in peripheral neuropathy associated with hepatitis C virus-related cryoglobulinemia. *J Neurol* 2014;261:725-31.
36. Feldman L, Dhamne M, Li Y. Neurologic manifestations associated with cryoglobulinemia: a single center experience. *J Neurol Sci* 2019;398:121-7.
37. Callaghan BC, Price RS, Chen KS, Feldman EL. The importance of rare subtypes in diagnosis and treatment of peripheral neuropathy: a review. *JAMA Neurol* 2015;72:1510-8.
38. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA et al. Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). *Muscle Nerve* 2009;39:116-25.
39. Scarpato S, Galassi G, Monti G, Mazzaro C, Mascia MT, Scaini P et al. Peripheral

neuropathy in mixed cryoglobulinaemia: clinical assessment and therapeutic approach.
Clin Exp Rheumatol 2020;38:1231-7.

[HOME](#)

[PRIVACY POLICY](#)

[5x1000 Docemus](#)

